J. Carlo Hojilla

J. Carlo Hojilla

Auto-generated profile, based on publicly available information

J. Carlo Hojilla

School of Nursing, California State University, Fullerton (Dr Nation, Messrs Pelayo and Trevino, and Ms Ambalada); College of Nursing, University of South Carolina, Columbia (Dr Raynor); Weill Institute for Neurosciences, Department of Psychiatry, University of California, San Francisco (Dr Hojilla); and American Nurses Association, SAMHSA Minority Fellowship Program, Silver Spring, Maryland (Dr Outlaw)

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 December 2017 in AIDS and Behavior
Verified
Journal Article
Closed access
PDF file
JHJ. Carlo Hojilla
J. Carlo Hojilla
DVDavid Vlahov
David Vlahov
PCPierre-Cedric Crouch
Pierre-Cedric Crouch
CDCarol Dawson-Rose
Carol Dawson-Rose
KFKellie Freeborn
Kellie Freeborn
ACAdam Carrico
Adam Carrico

3 April 2015 in AIDS and Behavior
Verified
Journal Article
Closed access
PDF file
JHJ. Carlo Hojilla
J. Carlo Hojilla
KKKimberly A. Koester
Kimberly A. Koester
SCStephanie E. Cohen
Stephanie E. Cohen
SBSusan Buchbinder
Susan Buchbinder
DLDeawodi Ladzekpo
Deawodi Ladzekpo
ALAlbert Y. Liu
Albert Y. Liu

25 March 2018 in Journal of the International AIDS Society
Verified
Journal Article
Open access
PDF file
JHJ Carlo Hojilla
J Carlo Hojilla
DVDavid Vlahov
David Vlahov
DGDavid V Glidden
David V Glidden
KAK Rivet Amico
K Rivet Amico
MMMegha Mehrotra
Megha Mehrotra
ACAdam W Carrico
Adam W Carrico
Introduction: Stimulant and heavy alcohol use are prevalent and associated with elevated risk for HIV seroconversion among men who have sex with men (MSM) and transgender women. In addition, each can pose difficulties for antiretroviral adherence among people living with HIV. Scant research has examined the associations of stimulant and heavy alcohol use with adherence to daily oral pre‐exposure prophylaxis (PrEP) among MSM and transgender women. To address this gap in the literature, we evaluated the hypothesis that stimulant use and binge drinking are prospectively associated with sub‐optimal PrEP adherence.Methods: We analysed data from participants in a nested case‐cohort in the iPrEx open label extension. Stimulant use (i.e. powder cocaine, crack‐cocaine, cocaine paste, methamphetamine, cathinone) and binge drinking (i.e. ≥5 drinks in a single day) in the last 30 days were assessed. Baseline urine was tested for stimulants using immunoassays to reduce misclassification. Sub‐optimal adherence was defined as tenofovir drug concentrations in dried blood spots less than 700 fmol per punch, indicative of less than four doses per week. We tested the prospective association of stimulant use and binge drinking with sub‐optimal adherence at the 4‐week follow‐up visit.Results and Discussion: Data from 330 participants were analysed. The majority of the participants were MSM (89%) with a median age at baseline of 29 years (interquartile range 24 to 39). Approximately 16% (52/330) used stimulants and 22% (72/330) reported binge drinking in the last 30 days. Stimulant users had fivefold greater odds of sub‐optimal PrEP adherence compared to non‐users in adjusted analysis (adjusted odds ratio [aOR] 5.04; [95% CI 1.35 to 18.78]). Self‐reported binge drinking was not significantly associated with sub‐optimal adherence after adjusting for stimulant use and baseline confounders (aOR 1.16 [0.49 to 2.73]). Depressive symptoms, being transgender, and number of sex partners were also not significantly associated with sub‐optimal PrEP adherence (p > 0.05).Conclusions: Stimulant use is a risk factor for sub‐optimal PrEP adherence in the month following PrEP initiation. Comprehensive prevention approaches that reduce stimulant use may optimize PrEP adherence. Creating adherence plans that specifically address PrEP dosing in the context of ongoing stimulant use should also be considered.

1 May 2022 in Annals of Plastic Surgery
Verified
Journal Article
Closed access
ATAnnie Tang
Annie Tang
JHJ. Carlo Hojilla
J. Carlo Hojilla
JJJordan E. Jackson
Jordan E. Jackson
KRKara A. Rothenberg
Kara A. Rothenberg
RGRebecca C. Gologorsky
Rebecca C. Gologorsky
KYKaren M. Yokoo
Karen M. Yokoo
Background: There are more than 150,000 transgender adolescents in the United States, yet research on outcomes after gender-affirming mastectomy in this age group is limited. We evaluated gender-affirming mastectomy incidence and postoperative complications, including regret, in adolescents within our integrated health care system. Methods: Gender-affirming mastectomies performed from January 1, 2013, to July 31, 2020, in adolescents 12 to 17 years of age at the time of referral were identified. The incidence of gender-affirming mastectomy was calculated by dividing the number of patients undergoing these procedures by the number of adolescents assigned female at birth aged 12 to 17 years within our system at the beginning of each year and amount of follow-up time within that year. Demographic information, clinical characteristics (comorbidities, mental health history, testosterone use), surgical technique, and complications, including mention of regret, of patients who underwent surgery were summarized. Patients with and without complications were compared to evaluate for differences in demographic or clinical characteristics using χ2 tests. Results: The incidence of gender-affirming mastectomy increased 13-fold (3.7–47.7 per 100,000 person-years) during the study period. Of the 209 patients who underwent surgery, the median age at referral was 16 years (range, 12–17 years) and the most common technique was double incision (85%). For patients with greater than 1-year follow-up (n = 137; 65.6%), at least one complication was found in 7.3% (n = 10), which included hematoma (3.6%), infection (2.9%), hypertrophic scars requiring steroid injection (2.9%), seroma (0.7%), and suture granuloma (0.7%); 10.9% underwent revision (n = 15). There were no statistically significant differences in patient demographics and clinical characteristics between those with and without complications (P > 0.05). Two patients (0.95%) had documented postoperative regret, but neither underwent reversal surgery at follow-up of 3 and 7 years postoperatively. Conclusions: Between 2013 and 2020, we observed a marked increase in gender-affirming mastectomies in adolescents. The prevalence of surgical complications was low, and of more than 200 adolescents who underwent surgery, only 2 expressed regret, neither of which underwent a reversal operation. Our study provides useful and positive guidance for adolescent patients, their families, and providers regarding favorable outcomes with gender-affirming mastectomy.

3 June 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MCMichelle Cespedes
Michelle Cespedes
MDMoupali Das
Moupali Das
JHJ. Carlo Hojilla
J. Carlo Hojilla
JBJill Blumenthal
Jill Blumenthal
KMKaram Mounzer
Karam Mounzer
OOOnyema Ogbuagu
Onyema Ogbuagu
Introduction: Black and Hispanic/Latinx cisgender men who have sex with men (MSM), transgender women, transgender men, and gender nonbinary (TGNB) individuals have been historically underrepresented in HIV pre-exposure prophylaxis (PrEP) clinical trials. There is an urgent need for ongoing engagement with communities that have been the most impacted by HIV and diverse representation in clinical trials. Here we describe strategic approaches undertaken in the PURPOSE 2 trial to optimize engagement of underrepresented individuals.Methods and results: PURPOSE 2 is an ongoing Phase 3 trial evaluating the safety and efficacy of lenacapavir as PrEP in cisgender MSM and TGNB individuals. In PURPOSE 2, we used a multipronged approach aimed at enriching participation of underrepresented individuals. We conducted a review to identify evidence-informed recommendations from literature, engaged with stakeholders, and established the Global Community Advisory and Accountability Group (GCAG) to represent the needs of the community. Insights from stakeholders and GCAG members resulted in an expansion of the study population to include transgender men, gender nonbinary persons, and adolescents, and evaluation of population-specific outcomes. Feedback from stakeholders and GCAG members also informed investigator and site selection; these were selected based on prior experience working with persons from diverse racial, ethnic and gender identities, and estimates of local HIV incidence. Site selection was also expanded to include community-based clinics with services tailored towards Black, Hispanic/Latinx, and TGNB populations. We established a study-wide recruitment goal of 50% Black MSM and 20% Hispanic/Latinx MSM in US sites and 20% transgender women globally. Site-specific recruitment goals were also developed based on local demographics and HIV incidence. Mandatory trainings included Good Participatory Practice guidelines, gender inclusivity, and antiracism.Conclusion: While further work is needed to achieve equitable representation, the strategies we describe may serve as a framework for future clinical trials.Trial registration: Clinical Trial Number:NCT04925752.

8 January 2021 in Drug and Alcohol Dependence
Verified
Journal Article
Closed access
DSDerek D. Satre
Derek D. Satre
TLTory Levine-Hall
Tory Levine-Hall
SSStacy A. Sterling
Stacy A. Sterling
KYKelly C. Young-Wolff
Kelly C. Young-Wolff
JLJennifer O. Lam
Jennifer O. Lam
MSMichael J. Silverberg
Michael J. Silverberg